vs
Cadre Holdings, Inc.（CDRE）与Enovis CORP（ENOV）财务数据对比。点击上方公司名可切换其他公司
Enovis CORP的季度营收约是Cadre Holdings, Inc.的3.3倍（$548.9M vs $167.2M）。Cadre Holdings, Inc.净利率更高（7.0% vs -104.1%，领先111.1%）。Enovis CORP同比增速更快（-2.2% vs -5.0%）。Enovis CORP自由现金流更多（$29.1M vs $18.0M）。过去两年Cadre Holdings, Inc.的营收复合增速更高（10.1% vs 9.8%）
Cadre Holdings, Inc.是美国金融科技企业，面向个人及机构客户提供房地产投资项目直投渠道，覆盖纽约等地的商业地产。公司打造的投资平台支持投资者自主选择参与的具体交易项目，且投资门槛远低于全额收购物业所需资金，让不动产投资变得更接近股票交易，获得财经媒体的广泛认可。
Enovis是一家专注于骨科领域的医疗科技企业，其前身是1995年由米切尔·雷尔斯和史蒂文·雷尔斯兄弟创立的科尔法克斯公司。公司总部位于特拉华州威尔明顿，目前在全球12个地点开展业务，拥有超过5000名员工，于纽约证券交易所上市，股票代码为ENOV。
CDRE vs ENOV — 直观对比
营收规模更大
ENOV
是对方的3.3倍
$167.2M
营收增速更快
ENOV
高出2.8%
-5.0%
净利率更高
CDRE
高出111.1%
-104.1%
自由现金流更多
ENOV
多$11.1M
$18.0M
两年增速更快
CDRE
近两年复合增速
9.8%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $167.2M | $548.9M |
| 净利润 | $11.7M | $-571.1M |
| 毛利率 | 43.4% | 59.9% |
| 营业利润率 | 12.2% | -101.7% |
| 净利率 | 7.0% | -104.1% |
| 营收同比 | -5.0% | -2.2% |
| 净利润同比 | -9.6% | 18.8% |
| 每股收益（稀释后） | $0.22 | $-9.99 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDREENOV
| Q4 25 | $167.2M | $548.9M | ||
| Q3 25 | $155.9M | $564.5M | ||
| Q2 25 | $157.1M | $558.8M | ||
| Q1 25 | $130.1M | — | ||
| Q4 24 | $176.0M | $561.0M | ||
| Q3 24 | $109.4M | $505.2M | ||
| Q2 24 | $144.3M | $525.2M | ||
| Q1 24 | $137.9M | $516.3M |
净利润CDREENOV
| Q4 25 | $11.7M | $-571.1M | ||
| Q3 25 | $10.9M | $-36.7M | ||
| Q2 25 | $12.2M | $-56.0M | ||
| Q1 25 | $9.2M | — | ||
| Q4 24 | $13.0M | $-703.2M | ||
| Q3 24 | $3.7M | $-31.5M | ||
| Q2 24 | $12.6M | $-18.6M | ||
| Q1 24 | $6.9M | $-72.0M |
毛利率CDREENOV
| Q4 25 | 43.4% | 59.9% | ||
| Q3 25 | 42.7% | 59.3% | ||
| Q2 25 | 40.9% | 59.5% | ||
| Q1 25 | 43.1% | — | ||
| Q4 24 | 43.9% | 54.8% | ||
| Q3 24 | 36.6% | 56.7% | ||
| Q2 24 | 40.6% | 55.0% | ||
| Q1 24 | 41.8% | 57.7% |
营业利润率CDREENOV
| Q4 25 | 12.2% | -101.7% | ||
| Q3 25 | 12.0% | -3.0% | ||
| Q2 25 | 9.3% | -8.4% | ||
| Q1 25 | 10.4% | — | ||
| Q4 24 | 16.7% | -118.5% | ||
| Q3 24 | 5.0% | -6.3% | ||
| Q2 24 | 13.8% | -8.4% | ||
| Q1 24 | 8.7% | -6.8% |
净利率CDREENOV
| Q4 25 | 7.0% | -104.1% | ||
| Q3 25 | 7.0% | -6.5% | ||
| Q2 25 | 7.8% | -10.0% | ||
| Q1 25 | 7.1% | — | ||
| Q4 24 | 7.4% | -125.4% | ||
| Q3 24 | 3.3% | -6.2% | ||
| Q2 24 | 8.7% | -3.5% | ||
| Q1 24 | 5.0% | -13.9% |
每股收益（稀释后）CDREENOV
| Q4 25 | $0.22 | $-9.99 | ||
| Q3 25 | $0.27 | $-0.64 | ||
| Q2 25 | $0.30 | $-0.98 | ||
| Q1 25 | $0.23 | — | ||
| Q4 24 | $0.32 | $-12.69 | ||
| Q3 24 | $0.09 | $-0.58 | ||
| Q2 24 | $0.31 | $-0.34 | ||
| Q1 24 | $0.18 | $-1.32 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $122.9M | $33.6M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | $317.8M | $2.0B |
| 总资产 | $770.0M | $4.4B |
| 负债/权益比越低杠杆越低 | — | 0.67× |
8季度趋势，按日历期对齐
现金及短期投资CDREENOV
| Q4 25 | $122.9M | $33.6M | ||
| Q3 25 | $150.9M | $44.1M | ||
| Q2 25 | $137.5M | $38.5M | ||
| Q1 25 | $133.4M | — | ||
| Q4 24 | $124.9M | $48.2M | ||
| Q3 24 | $93.0M | $35.4M | ||
| Q2 24 | $105.9M | $35.0M | ||
| Q1 24 | $87.1M | $66.3M |
总债务CDREENOV
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.3B | ||
| Q2 24 | — | $1.3B | ||
| Q1 24 | — | $1.3B |
股东权益CDREENOV
| Q4 25 | $317.8M | $2.0B | ||
| Q3 25 | $340.4M | $2.6B | ||
| Q2 25 | $332.5M | $2.6B | ||
| Q1 25 | $317.6M | — | ||
| Q4 24 | $311.5M | $2.6B | ||
| Q3 24 | $300.3M | $3.3B | ||
| Q2 24 | $299.4M | $3.3B | ||
| Q1 24 | $270.7M | $3.3B |
总资产CDREENOV
| Q4 25 | $770.0M | $4.4B | ||
| Q3 25 | $792.1M | $5.0B | ||
| Q2 25 | $794.4M | $4.9B | ||
| Q1 25 | $656.3M | — | ||
| Q4 24 | $652.7M | $4.7B | ||
| Q3 24 | $616.6M | $5.6B | ||
| Q2 24 | $620.6M | $5.4B | ||
| Q1 24 | $599.4M | $5.5B |
负债/权益比CDREENOV
| Q4 25 | — | 0.67× | ||
| Q3 25 | — | 0.54× | ||
| Q2 25 | — | 0.53× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.52× | ||
| Q3 24 | — | 0.40× | ||
| Q2 24 | — | 0.41× | ||
| Q1 24 | — | 0.40× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $21.3M | $82.6M |
| 自由现金流经营现金流 - 资本支出 | $18.0M | $29.1M |
| 自由现金流率自由现金流/营收 | 10.7% | 5.3% |
| 资本支出强度资本支出/营收 | 2.0% | 9.7% |
| 现金转化率经营现金流/净利润 | 1.81× | — |
| 过去12个月自由现金流最近4个季度 | $56.8M | $22.8M |
8季度趋势，按日历期对齐
经营现金流CDREENOV
| Q4 25 | $21.3M | $82.6M | ||
| Q3 25 | $22.5M | $47.8M | ||
| Q2 25 | $2.6M | $-1.6M | ||
| Q1 25 | $17.4M | — | ||
| Q4 24 | $23.7M | $88.3M | ||
| Q3 24 | $-5.2M | $53.6M | ||
| Q2 24 | $11.1M | $7.8M | ||
| Q1 24 | $2.1M | $-36.2M |
自由现金流CDREENOV
| Q4 25 | $18.0M | $29.1M | ||
| Q3 25 | $21.6M | $3.4M | ||
| Q2 25 | $1.2M | $-44.9M | ||
| Q1 25 | $16.1M | — | ||
| Q4 24 | $22.4M | $35.1M | ||
| Q3 24 | $-6.2M | $2.4M | ||
| Q2 24 | $9.1M | $-31.6M | ||
| Q1 24 | $794.0K | $-73.1M |
自由现金流率CDREENOV
| Q4 25 | 10.7% | 5.3% | ||
| Q3 25 | 13.9% | 0.6% | ||
| Q2 25 | 0.7% | -8.0% | ||
| Q1 25 | 12.4% | — | ||
| Q4 24 | 12.7% | 6.3% | ||
| Q3 24 | -5.7% | 0.5% | ||
| Q2 24 | 6.3% | -6.0% | ||
| Q1 24 | 0.6% | -14.2% |
资本支出强度CDREENOV
| Q4 25 | 2.0% | 9.7% | ||
| Q3 25 | 0.5% | 7.9% | ||
| Q2 25 | 0.9% | 7.7% | ||
| Q1 25 | 1.0% | — | ||
| Q4 24 | 0.7% | 9.5% | ||
| Q3 24 | 0.9% | 10.1% | ||
| Q2 24 | 1.4% | 7.5% | ||
| Q1 24 | 1.0% | 7.2% |
现金转化率CDREENOV
| Q4 25 | 1.81× | — | ||
| Q3 25 | 2.05× | — | ||
| Q2 25 | 0.21× | — | ||
| Q1 25 | 1.88× | — | ||
| Q4 24 | 1.83× | — | ||
| Q3 24 | -1.43× | — | ||
| Q2 24 | 0.89× | — | ||
| Q1 24 | 0.31× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDRE
| U.s.state And Local Agencies | $72.7M | 43% |
| Other | $48.6M | 29% |
| U.s.Federal Agencies | $31.6M | 19% |
| Commercial | $12.0M | 7% |
ENOV
| Reconstructive Segment | $258.0M | 47% |
| Surgical | $129.0M | 23% |
| Prevention And Recovery | $92.6M | 17% |
| Other Prevention And Recovery | $71.4M | 13% |
